High Rate of Second Neoplasms in Patients with a Bronchial Neuroendocrine Tumor Abstract #1745

Introduction: Bronchial neuroendocrine tumors (NETs) are classified as typical carcinoids (TC), atypical carcinoids (AC), large cell neuroendocrine carcinomas (LCNEC), or small cell lung carcinomas (SCLC)
Aim(s): We retrospectively reviewed the management, long-term follow-up and clinical outcome of bronchial NETs at our institution
Materials and methods: All patients diagnosed with TC, AC, or LCNEC at our institution from 1995 to 2015 have been included. Patients with SCLC were excluded. Clinical, diagnostic, therapeutic and follow-up data have been collected and analyzed
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Federica Alessandra Cavalcoli

To read results and conclusion, please login ...

Further abstracts you may be interested in

#173 Temozolomide in Metastatic Bronchial Carcinoids
Introduction: Metastatic bronchial carcinoids are rare neoplasms, where efforts of medical treatment thus far have been disappointing. Temozolomide has, however, shown some activity in a small prior study.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Daniel P Lindholm
#2166 A Family Bronchial Carcinoid Tumor.
Introduction: Typical and atypical bronchial carcinoids are neuroendocrine tumors of the lung. Family lung carcinoid tumors are rare and have been described as very rarely in literature.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Pr Bezzar-Ghomari Soumeyya
#1437 Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: A Subgroup Analysis of the Phase 3 RADIANT-4 Study
Introduction: In the phase 3, RADIANT-4 study, everolimus (EVE) improved median progression-free survival (PFS) by 7.1 months in patients (pts) with advanced, progressive, nonfunctional NET of lung or GI tract compared to placebo (PBO); HR, 0.48; 95%CI, 0.35-0.67; P<0.00001.
Conference: 13th Annual ENETS conference (2016)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Dr. Nicola Fazio
#749 Natural History of Atypical Carcinoid of Lung After Surgery
Introduction: The natural history of atypical carcinoid (AC) is poorly known.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Francesca Marciello
#1938 Eleven Years Survival after Combined Treatment of Surgery, Ultrasound-Guided Radiofrequency Ablation of Liver Metastasis, CT Embolization Plus Somatostatin LAR in a Case with Atypical Carcinoid of the Lung
Introduction: The combination of different therapeutic methods has an important place in the treatment of patients with NET and liver metastasis, ineligible for radical surgery.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Prof. Borislav Vladimirov
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.